8-K: Journey Medical Q2: Emrosi Drives Revenue, Loss Widens

Journey Medical Corporation reported a slight revenue increase to $15.0 million in Q2 2025, driven by Emrosi sales, but net loss widened to $3.8 million.

Summary

• Total net product revenues for Q2 2025 were $15.0 million, a slight increase from $14.9 million in Q2 2024.
• Emrosi, in its first full quarter on the market, generated net sales of $2.8 million.
• Gross margin improved to 67% in Q2 2025, up from 61% in the prior year quarter, due to product sales mix and lower product costs.
• Selling, general and administrative expenses increased by $1.6 million to $11.9 million in Q2 2025, primarily due to Emrosi launch and commercialization activities.
• Net loss for Q2 2025 was $3.8 million, or $(0.16) per share, compared to a net loss of $3.4 million, or $(0.17) per share, in Q2 2024.
• Adjusted EBITDA (non-GAAP) was $(0.5) million, or $(0.02) per share, in Q2 2025, a decrease from positive Adjusted EBITDA of $0.3 million, or $0.02 per share, in Q2 2024.
• Cash and cash equivalents remained stable at $20.3 million as of June 30, 2025, compared to December 31, 2024.
• Emrosi expanded payer access to over 100 million commercial lives in the U.S. by July 2025, up from 54 million in May 2025.
• The company joined the Russell 2000 and Russell 3000 Indexes effective June 27, 2025.
• Ramsey Alloush was appointed Chief Operating Officer in April 2025.

Sentiment

Score: 4

Explanation: While Emrosi's launch and revenue growth are positive, the widening net loss, negative Adjusted EBITDA, and the explicit 'going concern' risk significantly weigh down the sentiment. The company's financial stability is a major concern despite operational progress.

Positives

• Total net product revenues slightly increased to $15.0 million in Q2 2025.
• Emrosi generated strong initial net sales of $2.8 million in its first full quarter on the market, indicating strong traction.
• Gross margin significantly improved to 67% in Q2 2025 from 61% in Q2 2024, driven by favorable product sales mix and lower costs.
• Emrosi expanded payer access to over 100 million commercial lives in the U.S. by July 2025, a substantial increase from 54 million in May 2025.
• Inclusion in the Russell 2000 and Russell 3000 Indexes in June 2025 enhances visibility and liquidity.
• Cash and cash equivalents remained stable at $20.3 million.

Negatives

• Net loss widened to $3.8 million in Q2 2025 from $3.4 million in Q2 2024.
• Adjusted EBITDA turned negative, reporting $(0.5) million in Q2 2025 compared to positive $0.3 million in Q2 2024.
• Selling, general and administrative expenses increased by $1.6 million, impacting profitability.
• The company's ability to continue as a going concern is subject to substantial doubt, as explicitly stated in the risk factors.

Risks

• Products and product candidates are subject to time and cost intensive regulation and clinical testing, and may never be successfully developed or commercialized.
• A substantial portion of sales derive from products that may become subject to third-party generic competition, new competitor products, or increased market share of existing competitor products, which could adversely impact operating income.
• Operating in a heavily regulated industry, with unpredictable impacts from future legislation or administrative/executive action.
• Revenue is mainly dependent upon sales of dermatology products, and any setback could impair operating results.
• Competition could limit commercial opportunity and profitability, including from manufacturers of generic versions of products.
• Risk that products do not achieve broad market acceptance, including by government and third-party payors.
• Reliance on third parties for several aspects of operations.
• Dependence on the ability to identify, develop, and acquire or in-license products and integrate them into operations, which may be unsuccessful.
• Success of the business, including ability to finance and generate additional revenue, depends on the successful commercialization of Emrosi and any future product candidates.
• Clinical drug development is very expensive, time-consuming, and uncertain, and clinical trials may fail to adequately demonstrate the safety and efficacy of current or future product candidates.
• Competitors could develop and commercialize products similar or identical to ours.
• Risks related to the protection of intellectual property and potential inability to maintain sufficient patent protection for technology and products.
• Business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in cybersecurity.
• Substantial doubt about the ability to continue as a going concern.
• Effects of major public health issues, epidemics, or pandemics on product revenues and any future clinical trials.
• Potential need to raise additional capital.
• Fortress Biotech, Inc. controls a voting majority of common stock, which could be detrimental to other shareholders.

Future Outlook

Management believes Journey Medical is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond, driven by the strong traction of the Emrosi launch, continued improvement in cash generation, and the execution of its focused dermatology commercial organization.

Management Comments

• "We are pleased to report solid results for the second quarter of 2025, with total revenue of $15 million and a net sales contribution from Emrosi of $2.8 million during the period."
• "The second quarter marks the first full quarter since Emrosi entered the market, and in a short period of time, we have delivered a strong initial prescription ramp for the product while payer coverage continues to expand."
• "This momentum reflects growing physician and payer adoption, and confidence in Emrosis differentiated profile, including statistically superior efficacy versus Oracea and placebo, as published in the Journal of the American Medical Association (JAMA) Dermatology."
• "With the Emrosi launch showing strong traction out of the gate, continued improvement in cash generation, and the execution of our focused dermatology commercial organization, we believe Journey Medical is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond."

Industry Context

The dermatology pharmaceutical industry continues to see innovation and commercialization of new treatments for skin conditions. Journey Medical's focus on FDA-approved prescription products and the successful initial launch of Emrosi for rosacea positions it within this specialized market. The expansion of payer access for Emrosi is critical for market penetration and reflects the competitive landscape where broad coverage is essential for product success. The company's strategy of leveraging an efficient sales and marketing model aligns with trends in specialized pharma to optimize commercialization costs.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. However, Emrosi's reported 'statistically superior efficacy versus Oracea' (a registered trademark of Galderma Holdings, S.A. Socit Anonyme) suggests a competitive advantage against an established treatment for rosacea, indicating a strong product profile within the dermatology market.

Management Changes

Related Party Transactions

• The company was founded by Fortress Biotech, Inc. (Nasdaq: FBIO), and Fortress controls a voting majority of Journey Medical's common stock, which is disclosed as a risk factor for other shareholders.

Stakeholder Impact

• Shareholders: Potential for increased value from Emrosi's successful launch and market penetration, but significant risk due to widening losses and 'going concern' doubt. Fortress Biotech, as a majority shareholder, has significant control.
• Customers (patients/prescribers): Benefit from expanded access to Emrosi, a treatment for rosacea with demonstrated efficacy.
• Payers: Expanded commercial lives coverage for Emrosi indicates successful negotiation and adoption by insurance providers.
• Employees: Appointment of a new COO suggests organizational development, but overall financial health could impact job security if 'going concern' issues persist.

Next Steps

• Journey Medical management will conduct a conference call and audio webcast on August 12, 2025, at 4:30 p.m. ET to discuss the financial results and provide a business update.

Key Dates

Recommendation

The strong initial sales and expanding payer access for Emrosi are positive indicators for future revenue growth and market position in dermatology. The improved gross margin also suggests operational efficiency. However, the widening net loss, the shift to negative Adjusted EBITDA, and critically, the explicit disclosure of 'substantial doubt about our ability to continue as a going concern' present significant financial risks. While the product pipeline shows promise, the underlying financial stability is a major concern. An investor should hold to monitor if Emrosi's growth can offset the increasing losses and address the going concern risk, but new investment is not advisable given the current financial uncertainty.

Keywords

Dermatology, Pharmaceuticals, Emrosi, Rosacea, FDA-approved drugs, Commercial-stage, Financial results, SEC filing, Nasdaq, DERM, Biotech